ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer
LOS ANGELES, Aug. 13, 2020 /PRNewswire/ -- Akeso, Inc (9926.HK) - a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide - today announced that the U.S. Food and Drug Admini...
2020-08-13 20:07
6220
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee
LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...
2020-06-24 12:55
37
